Intravitreal panitumumab and myopic macular degeneration
Background: In experimental studies, intravitreally applied antibodies against epidermal growth factor (EGF), EGF family members (amphiregulin, neuregulin-1, betacellulin, epigen, epiregulin) and against the EGF receptor (EGFR) were associated with a reduction in lens-induced axial elongation and de...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 10, 2023
|
| In: |
British journal of ophthalmology
Year: 2024, Jahrgang: 108, Heft: 6, Pages: 859-864 |
| ISSN: | 1468-2079 |
| DOI: | 10.1136/bjo-2023-323383 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bjo-2023-323383 Verlag, lizenzpflichtig, Volltext: https://bjo.bmj.com/content/early/2023/07/10/bjo-2023-323383 
|
| Verfasserangaben: | Mukharram M Bikbov, Gyulli M Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan I Gilemzianova, Dinar A Khakimov, Jost B Jonas |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1881244997 | ||
| 003 | DE-627 | ||
| 005 | 20241209105702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjo-2023-323383 |2 doi | |
| 035 | |a (DE-627)1881244997 | ||
| 035 | |a (DE-599)KXP1881244997 | ||
| 035 | |a (OCoLC)1425200645 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bikbov, Mukharram |e VerfasserIn |0 (DE-588)1192393597 |0 (DE-627)1670731537 |4 aut | |
| 245 | 1 | 0 | |a Intravitreal panitumumab and myopic macular degeneration |c Mukharram M Bikbov, Gyulli M Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan I Gilemzianova, Dinar A Khakimov, Jost B Jonas |
| 264 | 1 | |c July 10, 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.02.2024 | ||
| 520 | |a Background: In experimental studies, intravitreally applied antibodies against epidermal growth factor (EGF), EGF family members (amphiregulin, neuregulin-1, betacellulin, epigen, epiregulin) and against the EGF receptor (EGFR) were associated with a reduction in lens-induced axial elongation and decrease in physiological eye elongation in guinea pigs and in non-human primates. Here, we investigated the intraocular tolerability and safety of a fully human monoclonal IgG2-antibody against EGFR, already in clinical use in oncology, as a potential future therapeutic approach for axial elongation in adult eyes with pathological myopia. - Methods The clinical, monocentre, open-label, multiple-dose, phase-1 study included patients with myopic macular degeneration of stage 4, who received intravitreal injections of panitumumab in various doses and in intervals ranging between 2.1 months and 6.3 months. - Results The study included 11 patients (age:66.8±6.3 years), receiving panitumumab injections in doses of 0.6 mg (4 eyes; 1×1 injection, 3×2 injections), 1.2 mg (4 eyes; 1×1 injection, 2×2 injections, 1×3 injections) and 1.8 mg (3 eyes; 1×1 injection, 2×2 injections), respectively. None of the participants showed treatment-emergent systemic adverse events or intraocular inflammatory reactions. Best-corrected visual acuity (1.62±0.47 logarithm of the minimal angle of resolution (logMAR) vs 1.28±0.59 logMAR; p=0.08) and intraocular pressure (13.8±2.4 mm Hg vs 14.3±2.6 mm Hg; p=0.20) remained unchanged. In nine patients with a follow-up of >3 months (mean:6.7±2.7 months), axial length did not change significantly (30.73±1.03 mm vs 30.77±1.19 mm; p=0.56). - Conclusions In this open-labelled, phase-1 study with a mean follow-up of 6.7 months, panitumumab repeatedly administered intravitreally up to a dose of 1.8 mg was not associated with intraocular or systemic adverse effects. During the study period, axial length remained unchanged. - Trial registration number DRKS00027302. | ||
| 650 | 4 | |a macula | |
| 650 | 4 | |a optics and refraction | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a retina | |
| 700 | 1 | |a Kazakbaeva, Gyulli M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Holz, Frank G. |d 1962- |e VerfasserIn |0 (DE-588)114875855 |0 (DE-627)549545182 |0 (DE-576)289811589 |4 aut | |
| 700 | 1 | |a Panda-Jonas, Songhomitra |e VerfasserIn |0 (DE-588)1063684919 |0 (DE-627)812456769 |0 (DE-576)40694797X |4 aut | |
| 700 | 1 | |a Gilemzianova, Leisan I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khakimov, Dinar A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jonas, Jost B. |d 1958- |e VerfasserIn |0 (DE-588)1028286732 |0 (DE-627)730536823 |0 (DE-576)37578537X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of ophthalmology |d London : BMJ Publ. Group, 1917 |g 108(2024), 6, Seite 859-864 |h Online-Ressource |w (DE-627)300594267 |w (DE-600)1482974-5 |w (DE-576)078993598 |x 1468-2079 |7 nnas |a Intravitreal panitumumab and myopic macular degeneration |
| 773 | 1 | 8 | |g volume:108 |g year:2024 |g number:6 |g pages:859-864 |g extent:6 |a Intravitreal panitumumab and myopic macular degeneration |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bjo-2023-323383 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://bjo.bmj.com/content/early/2023/07/10/bjo-2023-323383 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20240220 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1028286732 |a Jonas, Jost B. |m 1028286732:Jonas, Jost B. |d 60000 |e 60000PJ1028286732 |k 0/60000/ |p 7 |y j | ||
| 998 | |g 1063684919 |a Panda-Jonas, Songhomitra |m 1063684919:Panda-Jonas, Songhomitra |p 4 | ||
| 999 | |a KXP-PPN1881244997 |e 4488490468 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1136/bjo-2023-323383"],"eki":["1881244997"]},"name":{"displayForm":["Mukharram M Bikbov, Gyulli M Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan I Gilemzianova, Dinar A Khakimov, Jost B Jonas"]},"physDesc":[{"noteIll":"Illustrationen","extent":"6 S."}],"recId":"1881244997","relHost":[{"id":{"eki":["300594267"],"zdb":["1482974-5"],"issn":["1468-2079"]},"recId":"300594267","name":{"displayForm":["Institute of Ophthalmology. Ed. Sir Stewart Duke-Elder [u.a.]"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Intravitreal panitumumab and myopic macular degenerationBritish journal of ophthalmology","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1917-","dateIssuedKey":"1917","publisher":"BMJ Publ. Group","publisherPlace":"London"}],"note":["Gesehen am 03.12.12"],"pubHistory":["1.1917 -"],"title":[{"title":"British journal of ophthalmology","title_sort":"British journal of ophthalmology","subtitle":"BJO"}],"part":{"pages":"859-864","year":"2024","issue":"6","text":"108(2024), 6, Seite 859-864","volume":"108","extent":"6"},"titleAlt":[{"title":"BJO"}],"language":["eng"],"corporate":[{"role":"isb","display":"University of London"}]}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"July 10, 2023"}],"note":["Gesehen am 20.02.2024"],"title":[{"title":"Intravitreal panitumumab and myopic macular degeneration","title_sort":"Intravitreal panitumumab and myopic macular degeneration"}],"language":["eng"],"person":[{"given":"Mukharram","role":"aut","display":"Bikbov, Mukharram","family":"Bikbov"},{"given":"Gyulli M.","role":"aut","display":"Kazakbaeva, Gyulli M.","family":"Kazakbaeva"},{"given":"Frank G.","role":"aut","family":"Holz","display":"Holz, Frank G."},{"family":"Panda-Jonas","display":"Panda-Jonas, Songhomitra","role":"aut","given":"Songhomitra"},{"given":"Leisan I.","role":"aut","display":"Gilemzianova, Leisan I.","family":"Gilemzianova"},{"given":"Dinar A.","role":"aut","display":"Khakimov, Dinar A.","family":"Khakimov"},{"role":"aut","given":"Jost B.","display":"Jonas, Jost B.","family":"Jonas"}]} | ||
| SRT | |a BIKBOVMUKHINTRAVITRE1020 | ||